|
Title
|
Publication Date
|
Price
|
Relevance
|
Alzheimers Disease Antibodies
Competitor Analysis
|
Jul 2008 |
£83 |
100% |
|
Alzheimer's Disease Market Forecast
|
Nov 2010 |
£9,615 |
99% |
|
Epidemiology: Alzheimer's Disease
|
Dec 2010 |
£3,605 |
99% |
Understanding Alzheimer's Disease
Risk Factors, Genetics and Clinical Research
|
Nov 2010 |
£93 |
99% |
Early Diagnosis of Alzheimer's Disease
Benefits, Challenges and Recent Developments
|
Mar 2011 |
£315 |
99% |
Increasing Disease Burden of Alzheimer's Disease
Is There a Solution in Sight?
|
Mar 2011 |
£315 |
99% |
|
Alzheimer Disease Therapy Area Pipeline Report
|
Mar 2011 |
£945 |
98% |
Prescribing Influences: Alzheimer's Disease
Alleviating symptoms remains the goal for prescribers
|
Jun 2011 |
£2,405 |
98% |
Image-Based Biomarkers in Alzheimer's Disease
2011
|
Feb 2011 |
£350 |
98% |
Alzheimer's Disease
Pipeline Assessment and Market Forecasts to 2017
|
Nov 2010 |
£1,265 |
98% |
Alzheimer's Disease
Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011
|
Mar 2011 |
£1,500 |
98% |
|
U.S. Alzheimer's Disease Medication Market
|
Aug 2010 |
£3,795 |
98% |
|
Diagnostic and Therapeutic Trends in Alzheimer's Disease (Technical Insights)
|
Jun 2008 |
£4,110 |
98% |
|
Chinese Markets for Alzheimer Disease Drugs
|
Apr 2009 |
£2,530 |
98% |
Alzheimer's Disease Biomarkers in Cerebrospinal Fluid and Blood
2011
|
Feb 2011 |
£650 |
97% |
The 10th International Conference on Alzheimer's and Parkinson's Diseases
Post-Conference Review and Analysis
|
Mar 2011 |
£630 |
97% |
Alzheimer’s Disease Immunotherapy Pipeline
Vaccines, Therapeutic Antibodies and Emerging Strategies
|
Jul 2010 |
£1,500 |
97% |
|
Novel Targeted Therapies Hold Promise of Reversing the Progress of Alzheimer's Disease (AD)
|
Jan 2011 |
£315 |
97% |
|
CNS Drug Discoveries: Alzheimer's Disease Chapter
|
Aug 2008 |
£595 |
97% |
Tau and Amyloid Beta Targeted Therapy of Alzheimer's Disease
Competitor Analysis
|
Aug 2010 |
£580 |
97% |
|
Alzheimer's Disease: Competing Treatments and Market Entry Considerations
|
Jun 2010 |
£1,500 |
96% |
Alzheimer's Disease Global Clinical Trials Review
H2 2011
|
Oct 2011 |
£630 |
96% |
Alzheimer's and Parkinson's Diseases
A Global Update of Market Trends & Opportunities
|
Nov 2009 |
£1,895 |
96% |
Alzheimer’s Disease Patients & Market Worldwide
Future Scenario (2010 – 2015) & Drugs Analysis
|
Jun 2011 |
£600 |
96% |
Stakeholder Insight: Alzheimer's Disease
Prescribing trends indicate that neurologists are not adhering to guidelines
|
Dec 2006 |
£8,365 |
96% |
Alzheimer's Disease Therapeutics and Diagnostics
Global Markets
|
Jan 2010 |
£3,065 |
96% |
Alzheimer's Disease - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
96% |
Global Alzheimer Drugs Market
An Analysis
|
Mar 2009 |
£445 |
96% |
|
Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022
|
Oct 2007 |
£1,499 |
95% |
Stakeholder Opinions: Diagnostics in Neurology
Predictive Biomarkers Expand Drug Revenues
|
Jul 2008 |
£2,400 |
94% |
